Azacitidine is the effective treatment for AML patients intolerable to standard chemotherapy

Atsushi Hamamura

Presentation information

Poster Session

Sat.Oct,12

Poster Session 2-8 AML: Clinical Study/Case Reports

Sat. Oct 12, 2019 5:10 PM - 5:50 PM Poster (Tokyo International Forum, B2F Hall E)

Chair: Hisayuki Yokoyama (Department of Hematology and Rheumatology, Tohoku University Hospital)

[PS2-8-2] Azacitidine is the effective treatment for AML patients intolerable to standard chemotherapy

Atsushi Hamamura¹, Akihiko Nishijima¹, Yuki Osada¹, Kensuke Narukawa¹, Hina Takano², Gaku Oshikawa¹ (1.Department of Hematology, Japanese Red Cross Musashino Hospital, Tokyo, Japan, 2.Department of Transfusion, Japanese Red Cross Musashino Hospital, Tokyo, Japan)

Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.Password is written on a program book.